Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/telmisartan - Boehringer Ingelheim

Drug Profile

Amlodipine/telmisartan - Boehringer Ingelheim

Alternative Names: Amlodipine besylate/telmisartan; Micamlo Combination Tablets; Micardis Amlo; Micardis Anlo; Onduarp; Telmisartan/amlodipine; Telmisartan/amlodipine besylate; Twynsta

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Dec 2017 Chemical structure information added
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan/amlodipine for Hypertension in Japan
  • 29 Oct 2013 Boehringer Ingelheim plans a phase III trial for Hypertension (combination therapy) in Japan (NCT01975246)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top